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ABSTRACT
Objectives To evaluate risk factors associated with 
unfavourable outcomes: emergency care, hospitalisation, 
admission to intensive care unit (ICU), mechanical 
ventilation and death in patients with immune- mediated 
rheumatic disease (IMRD) and COVID-19.
Methods Analysis of the first 8 weeks of observational 
multicentre prospective cohort study (ReumaCoV Brasil 
register). Patients with IMRD and COVID-19 according to 
the Ministry of Health criteria were classified as eligible for 
the study.
Results 334 participants were enrolled, a majority of 
them women, with a median age of 45 years; systemic 
lupus erythematosus (32.9%) was the most frequent 
IMRD. Emergency care was required in 160 patients, 
33.0% were hospitalised, 15.0% were admitted to the 
ICU and 10.5% underwent mechanical ventilation; 28 
patients (8.4%) died. In the multivariate adjustment model 
for emergency care, diabetes (prevalence ratio, PR 1.38; 
95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 
95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) 
(PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy 
with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; 
p=0.001) remained significant; for hospitalisation, age >50 
years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of 
tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 
1.16 to 5.45; p=0.004) and methylprednisolone pulse 
therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for 
ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; 
p<0.001) and pulse therapy with methylprednisolone 
(PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two 
variables associated with death were pulse therapy with 
methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 
1.59 to 5.14; p<0.018).
Conclusions Age >50 years and immunosuppression 
with GC and cyclophosphamide were associated with 
unfavourable outcomes of COVID-19. Treatment with 
TNFi may have been protective, perhaps leading to the 
COVID-19 inflammatory process.
INTRODUCTION
Patients with immune- mediated rheumatic 
diseases (IMRD) are at increased risk of infec-
tions, with significant morbidity associated 
with serious infections, constituting one of 
the main causes of mortality in these patients.1 
Although previously published studies that 
evaluated patients with IMRD with COVID-19 
did not demonstrate an increased risk of 
more severe infections in these groups when 
compared with the general population,2–4 
these studies do not fully clarify whether 
patients with IMRD are at an increased risk 
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of developing more severe forms of COVID-19.5 6 More-
over, Brazil is a country of continental dimensions, with 
important regional differences in relation to socioeco-
nomic status, basic sanitation and access to health, and 
the evolution of patients with COVID-19 and IMRD may 
assume a different behaviour from other parts of the 
world.
The primary aim of this paper was to describe the 
patients included in the first 8 weeks of the ReumaCoV 
Brasil register, evaluating the factors associated with 
the following outcomes: (1) need for emergency care 
(patients who went to the hospital, except those who were 
seen in an outpatient clinic), (2) hospitalisation (more 
than 24 hours of hospital permanence), (3) intensive 
care unit (ICU) admission, (4) mechanical ventilation 
and (5) death. Our hypothesis was that patients with 
IMRD and high- grade immunosuppression could have 
an unfavourable evolution compared with those with less 
immunosuppression.
METHODS
The complete study methodology was previously 
published.7 Briefly, the ReumaCoV Brasil is a multicentre, 
observational, prospective cohort study carried out to 
monitor adult IMRD patients with COVID-19 diagnosis, 
using a convenience sample, whose data collection began 
20 May 2020, with inclusion scheduled until December 
2020, with 43 participating research centres.8 This paper 
will present the analysis of data for the first 8 weeks of 
inclusion in the study.
Eligible patients were selected based on the identifica-
tion of a case of COVID-19 by the researcher, through 
telephone contact, outpatient consultation or during 
hospitalisation for COVID-19. Inclusion criteria were: (1) 
age over 18, (2) COVID-19 diagnosis, according to the 
Brazilian Health Minister (BMH) (figure 1) and (3) prior 
diagnosis of IMRD, according to the American College 
of Rheumatology or the European League against 
Rheumatism criteria. Exclusion criteria were other 
immunodeficiency diseases, past organ or bone marrow 
transplantation, neoplasms within the last 5 years, current 
chemotherapy, HIV diagnosis and thymus diseases.
Demographic data such as age, sex, work situation 
and social isolation during the pandemic, as well diag-
nosis and treatment of IMRD, comorbidities (https://
www. who. int/ classifications/ icd/ icdonlineversions/ 
en/), clinical characteristics, treatment and evolution 
of COVID-19 were collected using a Research Eletronic 
Data Capture (REDCap) database (https://www. project- 
redcap. org/), through telephone call or face- to- face 
interview, if permitted by local health recommendations. 
In case of hospitalisation, the data were collected directly 
Figure 1 COVID-19 diagnosis established by the Brazilian Ministry of Health during the pandemic period. FS, flu syndrome.
Key messages
What is already known about this subject?
 ► Patients with immune- mediated rheumatic diseases (IMRD) are at in-
creased risk of infections.
 ► There are uncertainties as to whether patients with IMRD are at an in-
creased risk of developing more severe forms of COVID-19.
What does this study add?
 ► Patients with IMRD with COVID-19 did not demonstrate an increased risk 
of more severe infection in previous studies.
 ► High levels of immunosuppression with methylprednisolone or cyclo-
phosphamide pulse therapy and chronic oral GC were associated with 
unfavourable outcomes of the SARS- CoV-2 infection.
 ► Tumour necrosis factor inhibitor (TNFi) had an association with a lower 
prevalence of hospitalisation and need for intensive care unit admission.
How might this impact on clinical practice?
 ► Immunosuppressed patients should be routinely and even more careful-
ly evaluated for SARS- CoV-2 infection, as they may have unfavourable 
outcomes.
 ► In countries where the COVID-19 epidemic is on the rise, high- grade im-
munosuppression and GC should be stopped or reduced, as long disease 
activity allows.
 ► TNFi can be continued, as it appears to protect against severe forms of 
the disease.
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with the patient, if possible, or from medical records. 
In cases where death was notified, data were collected 
directly from a family member, who authorised the inclu-
sion of the data in the register.
For data analysis, a database was built using the REDCap 
database, which was exported to the SPSS program, V.21, 
where the analysis was performed. To characterise the 
profile of the patients, the percentage of frequencies 
were calculated, and the frequency distribution of the 
evaluated factors was constructed. For the quantitative 
variables, the median and IQR statistics were calculated. 
In order to verify which factors influenced the outcomes, 
the contingency table was constructed and the Chi- square 
test for the independence sample was applied. In cases 
where the assumptions of the χ2 test were violated, Fish-
er’s exact test was applied. In addition, prevalence ratios 
(PR) and the respective CI were calculated. Since the 
objective of the study was to assess the evolution of the 
most severe forms of COVID-19 in patients with IMRD, 
the IUC and death outcomes were analysed only among 
patients who were hospitalised.
All conclusions were drawn considering the signif-
icance level of 5%. The variables that showed statis-
tical significance of up to 20% in the bivariate analysis 
were included in the Poisson multivariate adjustment. 
Variables with a 5% significance remained in the final 
model. The OR was calculated to assess the chance of a 
COVID-19 symptom occurring in patients with laboratory 
confirmed disease.
This study was registered at the Brazilian Registry of 
Clinical Trials—REBEC, RBR- 33YTQC. All patients read 
and signed the informed consent form before inclusion.
RESULTS
Results are reported in accordance with STROBE guide-
lines. Between 20 May 20 and 24 July 2020, 334 IMRD 
patients with a diagnosis of COVID-19 were included 
in the register. The median age was 45 years (IQR=31–
57) and 81.4% were female. In regard to their work 
situation, 186 (55.0%) patients were active at the time 
of SARS- CoV-2 infection; among the inactive, most 
were retired or on work leave due to rheumatic disease 
(69.0%); 126 (37.3%) patients reported a profession 
that dealt directly with the public (public attendance, 
health, security, education); 159 (47.0%) patients 
reported no social isolation during the pandemic; 159 
(47.0%) reported close contact with a confirmed case of 
COVID-19, with 104 (30.8%) events occurring at home. 
The most common comorbidities were hypertension 
(35.8%), obesity (15.7%) and diabetes (11.5%); smoking 
was reported by 4.4% of patients. Regarding rheumatic 
disease diagnosis, systemic lupus erythematosus (SLE) 
(32.9%) and rheumatoid arthritis (RA) (28.4%) were the 
most frequent. Hydroxychloroquine (HCQ) (118/338; 
34.9%), oral glucocorticoids (GC) (116/338; 34.2%), 
tumour necrosis factor inhibitor (TNFi) (75/338; 
22.2%) and methotrexate (68/338; 20.1%) were the 
most common rheumatic disease treatments. All patients 
included were COVID-19 confirmed cases, according to 
BMH recommendations (figure 1), most of them classi-
fied according to lab criterion (76.8%), mostly through 
RT- PCR (n=175; 51.8%). Table 1 describes demographic 
and clinical data of the sample.
In regard to COVID-19 symptoms, the most frequent 
were headache (58.0%), cough (56.5%) and fever 
(51.2%). Twelve asymptomatic patients (3.6%) were 
included because they presented a positive RT- PCR for 
SARS- CoV-2, collected due to contact with a confirmed 
case of COVID-19.
The median duration of symptoms was 12 days 
(IQR=10) and 102 patients (30.2%) still had symptoms at 
study entry. The most common medications used to treat 
COVID-19 were analgesics (n=166, 49.6%) and azithro-
mycin (n=165, 49.3%), HCQ (n=66, 19.7%) and oral GC 
(n=71, 20.6%), at a dosage above >30 mg/day in 44.1% 
of patients. Pulse therapy with GC was used by 14 (4.2%) 
patients.
Regarding the main outcomes, emergency care was 
required in 160 patients (48%); 110 (33.0%) patients 
were hospitalised, 50 (15.0%) were admitted to the 
ICU, 35 (10.5%) underwent mechanical ventilation and 
28 (8.4 %) died. Among the 28 patients who died, 24 
(85.7%) were women, and the median age was 53 years 
(IQR 36–69). The diagnosis was SLE in 11 patients, 4 were 
RA, 2 axial spondyloarthritis, 5 systemic sclerosis and 6 
had other diseases; 5 (17.9%) patients were using pulse 
therapy with methylprednisolone and 5 (17.9%) patients 
were using pulse therapy with cyclophosphamide.
Table 2 describes the binary associations between the 
need for emergency care and explanatory variables only 
in the COVID-19 lab confirmed group. There was a statis-
tically significant difference in relation to being inactive 
at work (PR 1.42, 95% CI 1.13 to 1.78; p=0.002), the pres-
ence of diabetes (PR 1.49, 95% CI 1.18 to 1.87; p=0.008), 
and having hypertension (PR 1.30, 95% CI 1.05 to 1.62; 
p=0.020), hypothyroidism (PR 1.52, 95% CI 1.17 to 1.98; 
p=0.030), kidney disease (PR 1.49, 95% CI 1.13 to 1.97; 
p=0.046), using oral corticosteroids (PR1.60, 95% CI 1.30 
to 1.97; p<0.001) and methylprednisolone pulse therapy 
(PR 1.86, 95% CI 1.65 to 2.08; p=0.018). Not using TNFi 
was associated with an increased prevalence rate for 
hospitalisation (PR 1.53; 95% CI 1.07 to 2.18; p=0.007). 
No differences were observed regarding age, gender, 
social isolation, heart and lung disease, obesity, smoking, 
HCQ, methotrexate, leflunomide or rheumatic disease 
diagnosis.
In the multivariate adjustment using the Poisson model 
for emergency care, diabetes, kidney disease, use of oral 
GC and pulse therapy with methylprednisolone remained 
significant (table 3).
Table 4 shows the binary associations between the 
primary outcomes: hospitalisation, ICU, mechan-
ical ventilation, death and explanatory variables. For 
hospitalisation, a statistically significant association was 
observed with age >50 years (PR 1.91; 95% CI 1.26 to 
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2.91; p=0.002), not using TNFi (PR 2.69; 95% CI 1.26 
to 2.91; p=0.005), oral GC (PR 1.82; 95% CI 1.1 to 2.74; 
p=0.005), oral GC dose above 20 mg/day (PR 2.18; 95% 
CI 1.29 to 3.66; p=0.007) and methylprednisolone pulse 
therapy to treat rheumatic disease (PR 2.90; 95% CI 
1.73 to 4.87; p=0.014). In multivariate analysis using the 
Poisson model, age >50 years, and not using TNFi and 
methylprednisolone pulse therapy remained statistically 
significant (table 3).
Regarding admission to the ICU, a statistically signif-
icant association was observed with oral GC (PR 2.15, 
95% CI 1.32 to 3.48; p=0.001), not using TNFi (PR 2.59; 
95% CI 0.88 to 7.57), pulse therapy with methylprednis-
olone or cyclophosphamide for rheumatic disease treat-
ment (PR 2.26, 95% CI 1.33 to 3.85; p=0.042), with these 
last two also associated with increased risk of death (PR 
2.86, 95% CI 1.59 to 5.14; p=0.018) (table 4). In multivar-
iate analysis using the Poisson model, oral CE and pulse 
therapy with methylprednisolone remained statistically 
significant SLE was shown to have a possible protective 
effect for IUC in the multivariate (table 3). None of the 
Table 1 Demographic and clinical characteristics of 




Age, median (IQR) 45 (31–57)
Professions that deal with the public 126 37.3
Active at work 186 55.0
Retired/ work leave due rheumatic 
disease*
230 69.0
Social isolation 159 47.0




  Hypertension 121 35.8
  Obesity 53 15.7
  Diabetes 39 11.5
  Hypothyroidism 20 5.9
  Lung disease 32 9.4
  Heart disease 25 7.4
  Dyslipidaemia 22 6.5
  Fibromyalgia 12 3.6
  Kidney disease 21 6.2
  Smoking 15 4.4
  Alcoholism 8 2.4
  Depression 7 2.1
Rheumatic diseases diagnostic
  Systemic lupus erythematosus 110 32.9
  Rheumatoid arthritis 95 28.4
  Axial Spondyloarthritis 45 13.5
  Systemic sclerosis 23 6.9
  Psoriatic arthritis 23 6.9
  Vasculitis 10 3.3
  Others 28 8.3
Rheumatic disease treatment
  Hydroxychloroquine 118 34.9
  Oral corticosteroids 116 34.3
  Methotrexate 68 20.1
  Azathioprine 42 12.4
  Leflunomide 23 11.8
  Mycophenolate mofetil 21 6.2
  TNFi 75 22.2
  Non- TNFi 41 12.1
   Rituximab 13 3.8
   Anti- IL-17 12 3.6
   Tocilizumab 9 2.7
   Belimumab 3 0.9
   Abatacept 3 0.9
Continued
Variables n %
   Anti- IL12-23 1 0.3
  JAK- inhibitors 12 3.6
  Cyclophosphamide (pulse therapy) 10 3.0
  Methylprednisolone (pulse therapy) 8 2.4
COVID-19 symptoms
  Cough 195 56.7
  Shortness of breath 160 46.5
  Headache 200 58.0
  Asthenia 165 47.9
  Fever 176 51.2
  Anosmia 153 44.4
  Rhinorrhea 111 32.2
  Joint pain 72 21.0
  Myalgia 140 40.8
  Dysgeusia 146 42.3
COVID-19 lab confirmation 255 76.0
  RT- PCR 175 51.8
  SARS- CoV-2 Serology (IgM or IgG) 98 29.3
  Unknown 30 8.9
Emergency care 160 48.0
  Hospitalised 110 33.0
  Discharge alive 66 19.8
  Intensive unit care 50 15.0
  Mechanical ventilation 35 10.5
  Death 28 8.4
*Among 148 inactive at work
GC, glucocorticoids; IL-17, interleukin 17; JAK, Janus kinase; 
TNFi, tumour necrosis factor inhibitor.
Table 1 Continued
 on M
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p- value PR 95% CIYes (n, %) No (n, %)
Age
  Up to 50 years 81 (52.9) 72 (47.1) 0.429* 1.00; –
  >50 years 58 (58.0) 42 (42.0) 1.10; 0.88 to 1.37
Sex
  Male 25 (53.2) 22 (46.8) 0.769* 1.00; –
  Female 115 (55.6) 92 (44.4) 1.04; 0.78 to 1.40
Work situation
  Inactive 73 (65.2) 39 (34.8) 0.002* 1.42; 1.13 to 1.78
  Active 63 (46.0) 74 (54.0) 1.00; –
Skin colour
  White 78 (56.9) 59 (43.1) 0.529* 1.07; 0.86 to 1.34
  Non white 62 (53.0) 55 (47.0) 1.00; –
Geographic distribution
  Non- southeast 58 (49.6) 59 (50.4) 0.101* 1.00; –
  Southeast 82 (59.9) 55 (40.1) 1.21; 0.96 to 1.52
Hypertension
  No 81 (49.7) 82 (50.3) 0.020* 1.00; –
  Yes 59 (64.8) 32 (35.2) 1.3 1.05 to 1.62
Obesity
  No 113(53,6) 98(46,4) 0.267* 1.00; –
  Yes 27(62,8) 16(37,2) 1.17 0.90 to 1.52
Diabetes
  No 116 (52.0) 107 (48.0) 0.008* 1.00; –
  Yes 24 (77.4) 7 (22.6) 1.49 1.18 to 1.87
Lung disease
  No 121 (54.3) 102 (45.7) 0.461* 1.00; –
  Yes 19 (61.3) 12 (38.7) 1.13 0.83 to 1.53
Cardiovascular disease
  No 124 (53.7) 107 (46.3) 0.144* 1.00; –
  Yes 16 (69.6%) 7 (30.4) 1.3 0.96 to 1.74
Dyslipidaemia
  No 129 (54.4) 108 (45.6) 0.411* 1.00; –
  Yes 11 (64.7) 6 (35.3) 1.19 0.82 to 1.72
Hypothyroidism
  No 127 (53.4) 111 (46.6) 0.030* 1.00; –
  Yes 13 (81.3) 3 (18.8) 1.52 1.17 to 1.98
Kidney disease
  No 128 (53.6) 111 (46.4) 0.046* 1.00; –
  Yes 12 (80.0) 3 (20.0) 1.49 1.13 to 1.97
Smoking
  No 136 (56.0) 107 (44.0) 0.228† 1.54 0.70 to 3.39
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tested variables were associated with mechanical ventila-
tion (table 4).
Before including the use of TNFi in the binary analysis, 
it was tested whether there was an association with the 
use of biologicals of all classes as a group, and an asso-
ciation was observed with the ICU outcome (p=0.001). 
However, when we separated the groups into biological 
TNFi (p=0.006) and non TNFi (p=0.089), the difference 
remained only for the TNFi group. For this reason, only 
this group was included in the binary analysis and Poisson 
model.
DISCUSSION
Brazil is the country with the third highest number 
of cases of COVID-19 in the world, with the first case 
confirmed 26 February 2020, and counting 4 123 000 
cases and 126 203 deaths through 6 September 2020.9 
To the best of our knowledge, ReumaCoV Brasil is the 
largest cohort of patients with COVID-19 and underlying 
IMRD from a single country. Our results demonstrate 
that age over 50, diabetes, kidney disease, use of oral GC, 
not using TNFi, pulse therapy with methylprednisolone 
and cyclophosphamide were associated with a higher 
prevalence of worse outcomes of COVID-19 in patients 
with IMRD. We did not find any association between the 
variables and the need for mechanical ventilation.
The first published report regarding COVID-19 in 
patients with rheumatic diseases suggested that there 
would be no greater risk in relation to the general popu-
lation or with other comorbidities.3 10 Since then, some 
studies addressed the risk and severity of COVID-19 infec-
tion in people with IMRD, confirming this initial impres-
sion, except for hospitalisation in patients exposed to 
high GC doses.11 However, evidence on COVID-19 risk 
Variables
Emergency care
p- value PR 95% CIYes (n, %) No (n, %)
  No 133 (54.5) 111 (45.5) 0.519† 1.00; –
  Yes 7 (70.0) 3 (30.0) 1.28 0.84 to 1.96
Alcoholism
  No 137 (55.9) 108 (44.1) 0.049† 3.91 0.64 to 24.11
  Yes 1 (14.3) 6 (85.7) 1.00; –
Depression
  No 137 (55.2) 111 (44.8) 1.000† 1.1 0.49 to 2.48
  Yes 3 (50.0) 3 (5.,0) 1.00; –
TNFi
  No 119 (59.5) 81 (40.5) 0.007* 1.53 1.07–2.18
  Yes 21 (38.9) 33 (6.1) 1.00; –
HCQ
  No 86 (51.2) 82 (48.8) 0.079* 1.00; –
  Yes 54 (62.8) 32 (37.2) 1.23 0.98 to 1.53
Oral GC
  No 80 (46.2) 93 (53.8) <0.001 1.00; –
  Yes 60 (74.1) 21 (25.9) 1.6 1.30 to 1.97
GC dosage
  <20 mg/day 43 (69.4) 19 (30.6) 0.133† 1.00; –
  ≥20 mg/day 17 (89.5) 2 (10.5) 1.29 1.03 to 1.62
Intravenous GC
  No 133 (53.8) 114 (46.2) 0.018† 1.00; –
  Yes 7 (100.0) 0 (0,0) 1.86 1.65 to 2.08
CYC
  No 133 (54.3) 112 (45.7) 0.193† 1.00; –
  Yes 7 (77.8) 2 (22.2) 1.44 1.00 to 2.09
*P value of the χ2 test for independence;
†P value of Fisher’s exact test.
CYC, cyclophosphamide pulse therapy; GC, glucocorticoids; HCQ, hydroxychloroquine; Methyl, methylprednisolone e pulse therapy; PR, 
prevalence ratio; TNFi, tumour necrosis factor inhibitor.
Table 2 Continued
 on M
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and outcome in patients with systemic autoimmune 
diseases is limited and conflicting and should be inter-
preted with great caution.
Almost half of the patients in our study required emer-
gency care, being more prevalent among patients with 
diabetes, kidney disease and chronic users of corticoste-
roids, either oral or in the form of pulse therapy. Among 
those who sought emergency care, there was the need 
for hospitalisation in two thirds of cases, especially in 
older patients, those who were treated with methylpred-
nisolone pulse therapy and those who did not use TNFi. 
The prevalence is higher than those reported in most 
published studies,11–16 and similar to that reported in an 
Italian cohort by Fredi et al.17 One possible explanation 
for these differences is the lower social conditions in 
Brazil, which makes patients more susceptible to more 
severe conditions, besides the difference in the patient’s 
disease profile and medications, raising the need for 
greater concern for patients in developing countries. In 
accordance with ReumaCov Brazil, most of the studies 
have found advanced age associated with a higher risk of 
hospitalisation.13 15–18
Chronic GC use, both oral and pulse therapy, was 
associated with all outcomes, except mechanical venti-
lation. Other previous studies describe similar results 
with oral GC, with doses ranging from 5 to 10 mg11 12 14 19; 
however, none of these studies described the impact of 
pulse therapy with methylprednisolone to treat IMRD in 
COVID-19 outcomes. Although recent studies have shown 
that the use of GC s in the moderate to severe acute phase 
of COVID-19 has led to a benefit,20 21 the effect seems 
to be deleterious in patients on chronic use, probably 
associated increased risk of infection with higher dose 
of GC,22 due to impairment of innate immune responses 
with a reduction in neutrophil recruitment and a delay in 
viral clearance.23
The result that associated lower prevalence of hospital-
isation and ICU admission in patients using TNFi therapy 
is similar to that described in other studies12–14 and could 
not be demonstrated to all classes of biologicals. We must 
also consider that the number of patients using non- TNFi 
biologicals was lower (12.1%), therefore, the data should 
be interpreted with caution. However, other studies, 
including populations with different diseases, have shown 
similar results, which demonstrates that there must be a 
biological plausibility for this effect.11 24 25 Gianfrancesco 
et al also reported that TNFi use was associated with 
reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 
to 0.81), a finding that was not seen with conventional 
DMARDs alone or in combination with biologics or Janus 
kinase inhibitors.11
A possible explanation for the TNFi effect on 
COVID-19 could be inflammation control, based on the 
evidence that patients with more severe COVID-19 have 
higher levels of cytokines as TNF and IL-6,26–28 and the 
TNF inhibition in animal models has led to a protection 
against SARS- CoV-2 infection,29 induces a rapid decrease 
of IL-6 and IL-1 concentrations in patients with active 
RA,30 triggers a reduction of adhesion molecules and 
vascular endothelial growth factor, which is partly respon-
sible for capillary leak,31 with a consequence of less leuco-
cyte traffic to inflamed tissues.32 A similar effect was also 
observed in other viral infections, such as Chikungunya 
fever, where the use of TNFi was associated with better 
outcomes.33
Twenty- eight patients died, accounting for 8.4% 
of the total of our series and 17.5% of hospitalised 
Table 3 Multivariate adjustment using the Poisson model 
for emergency care, hospitalisation and intensive unit care 
admission
Variables PR 95% CI P value*
Emergency care
Diabetes
  No 1.00 –
  Yes 1.38 1.11 to 1.73 0.004
Kidney disease
  No 1.00 –
  Yes 1.36 1.05 to 1.77 0.020
Oral GC
  No 1.00 –
  Yes 1.49 1.21 to 1.85 <0.001
Intravenous GC
  No 1.00 –
  Yes 1.38 1.14 to 1.67 0.001
Hospitalisation
Age
  Up to 50 1.00 – –
  >50 1.89 1.26 to 2.85 0.002
TNFi
  No 2.51 1.16 to 5.45 0.020
  Yes 1.00 – –
Intravenous GC
  No 1.00 – –
  Yes 2.50 1.59 to 3.92 <0.001
Intensive care unit admission
Oral GC
  No 1.00 – –
  Yes 2.24 1.36 to 3.71 0.002
Intravenous GC
  No 1.00 – –
  Yes 1.65 1.0 to 2.68 0.043
SLE
  No 1.00 –
  Yes 1.72 1.04 to 2.88 0.036
*P value of the Wald test
PR, prevalence ratio; TNFi, tumour necrosis factor inhibitor; GC, 
glucocorticoids; SLE, systemic lupus erythematosus.
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patients, which is quite similar to the data found in other 
cohorts.11–13 17 19 The factors associated with mortality in 
these various studies were variable, but the use of oral GC 
was the common factor for most of them. In our study 
deaths were associated with pulse therapy with methyl-
prednisolone and cyclophosphamide. The impact of 
these medications on both hospitalisation and mortality 
may be due to the greater number of patients with SLE 
included in our cohort when compared with others, but 
also the greater number of SLE among the deaths. It is 
noteworthy that patients treated with these medications 
have more severe disease, especially in SLE. This fact 
calls attention to the evaluation of treatment alternatives 
during the COVID-19 pandemic, with lower doses of GC 
and other immunosuppressants than cyclophosphamide, 
once this is possible.
HCQ was not protective against COVID-19. Despite 
some initial promising in vitro results,34 35 this hypoth-
esis was not supported by our results or by the results 
of other studies performed in pre- exposed and postex-
position prophylaxis using HCQ, as well as more recent 
randomised clinical trials, including mild- moderate and 
severe forms of COVID-19.36–39 More recently, Gianfran-
cesco et al reported no association of antimalarial use 
(OR 0.94, 95% CI 0.57 to 1.57) with hospitalisation.11
Patients with rheumatic diseases had greater need 
for ICU hospitalisation and presented over a threefold 
increased risk of requiring mechanical ventilation.15 
Here, we report that 35 out of 50 patients in the ICU 
required invasive mechanical ventilation, corresponding 
to 70% of the patients in the ICU. This represents a need 
for ventilatory assistance in a higher proportion than 
described in other cohorts of IMRD patients and in the 
general population.40
Other important points addressed by our study deserve 
to be highlighted, as they demonstrate a different profile 
from other data previously published. As in the other 
series, there was a predominance of females, probably 
reflecting the higher prevalence of IMRD in women.11 17 
However, different from other studies, our patients were 
younger11 17 19 and most of those who died were women 
under the age of 60 (median 53 years). Considering the 
median age of 45 years of patients in our cohort, and 
the mean age of the patients that died, it suggests that 
immunosuppression is a relevant factor associated with 
mortality in COVID-19. The immunosuppressed, younger 
patients can be more vulnerable, and should be consid-
ered as a group for shielding. Although our patients were 
younger, more than two- thirds were not working, and 
among those who were active at work, most performed 
activities involving care or contact with the public, which 
may have favoured infection by SARS- CoV-2. Less than 
half reported social isolation, suggesting a lack of confi-
dence in social distancing measures or for being consid-
ered as breadwinners. Compared with other cohorts, in 
which SLE patients comprise 6.5%–19.0%, we have found 
a higher proportion (32.9%).11–13 15 17 Some cohorts that 
evaluated only SLE patients demonstrated a higher rate 
of hospitalisation41 42 with no difference between those 
who used or did not use HCQ and also with no differ-
ence in relation to the need for mechanical ventilation or 
extracorporeal membrane oxygenation.41 43
Although the most recent systematic review and 
meta- analysis44 has shown the IMRD patients are more 
susceptible to the COVID-19, including unfavourable 
outcomes, when SLE patients are separately analysed, 
particularly in case–control studies, this finding does not 
seem to be an absolute true. It probably reflects a selec-
tion bias, frequently reported by observational studies, 
similar to our findings, since most research centres have 
a great number of SLE patients, with easy access to the 
researcher and to hospital. In addition, these patients 
could have been more frequently hospitalised because 
the clinician may have considered the potential severity 
of the disease in the COVID-19 scenario. In the multivar-
iate analysis, having a diagnosis of SLE was considered 
as a possible protective effect for ICU. Nonetheless, it is 
worth emphasising that SLE patients may have the combi-
nation of infection and disease activity in the context of 
immunosuppression and the rheumatologist needs to 
individualise the treatment weighing benefits and risks. 
Interestingly, the current reports have not shown reacti-
vation of underlying IMRD after the COVID-19.45 46 Thus, 
large and longitudinal studies are necessary to address 
this relevant issue.
In the 74 Latin American patients with rheumatic 
diseases and COVID-19 reported from the COVID-19 
Global Rheumatology Alliance Physician- Reported 
Registry there were more RA patients (35%) than SLE 
patients (22%), while in our sample the proportion of 
SLE patients (32,9%) was greater than the RA (28,4%).47
Although hypertension and diabetes were the most 
frequent comorbidities, as described in other cohorts, 
we observed that diabetes and renal diseases were the 
two diseases associated with emergency care at the final 
model. Of interest, we found 15.7% of obesity, which was 
not frequently described in other cohorts, but almost the 
same to one multicentric cohort.13 15 18
A strength of our study is that we included patients 
from different states of Brazil, a continental country, 
with most of the patients with confirmed diagnosis of 
COVID-19 based on positive COVID-19 RT- PCR testing. 
In addition, the 8- week interim analysis is related to the 
first weeks of community viral transmission, a relevant 
finding simulating the pandemic epidemiological curve 
in Brazil.48
As a limitation of the study, many cases may be not 
included in the cohort because they were not tested 
or have not been confirmed, usually for presenting a 
benign evolution of the disease. Since in the Brazilian 
public health system only hospitalised patients were 
being tested, this may have become a selection bias, 
including only the most severely ill patients. Because this 
is a national register, patients were treated in different 
services, possibly with different physical and personnel 
characteristics—a fact that may have interfered with the 
 on M










pen: first published as 10.1136/rm




11Marques CDL, et al. RMD Open 2021;7:e001461. doi:10.1136/rmdopen-2020-001461
Infections
results. The availability of healthcare in Brazil can be 
different when it comes to the public or private health 
system. Regarding treatment, it was not possible to eval-
uate the association between COVID-19 with the combi-
nation use of different immunosuppressants or DMARDs 
combination.
Another limitation is related to main endpoints, 
including hospitalisation, need of mechanical ventilation 
and death, because they could not be adjusted for poten-
tial bias, such as access to healthcare systems, availability 
of hospital beds, strategies to mitigate the community 
viral transmission, heterogeneous expertise of medical 
team.49 50 Physicians’ beliefs on the risk of poor outcome 
in IMRD patients, especially those under immunosup-
pression, could have driven decision making, such as the 
need of ICU and medications given earlier. However, it 
is also important to consider that some patients enrolled 
in our registry had active and severe underlying IMRD. 
Therefore, the unfavourable evolution of them could 
occur itself, regardless of COVID-19.
Brazil is a country with a heterogeneous population, 
with variations in socioeconomic, cultural, ethnic and 
health status. The fact that we included representative 
patients from all Brazilian geographic regions allows our 
results to be generalised to Brazil and possibly to Latin 
American countries, with the same population pattern. 
Future studies comparing the different populations are 
needed to confirm whether these data occur similarly or 
not in the rest of the world.
In conclusion, the results of first 8 weeks of the 
ReumaCoV Brazil registry showed that aspects related 
to the patients with IMRD (age >50 years), and those 
related to their treatment (immunosuppression with GC 
and cyclophosphamide) were associated with unfavour-
able outcomes of the SARS- CoV-2 infection. Treatment 
with TNFi, on the other hand, may have been protective, 
perhaps leading to the control of COVID-19 inflamma-
tory process, but randomised controlled trials to prove 
this effect are needed.
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